Markets
GH Research PLC (GHRS)
GHRSNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$18.49
0.0000 (0.00%) today
At the close, Nov 12, 4:00 PM ET. Pre-market $18.55 +0.35%
-3.52% 1D
- Market cap
- $1.27bn
- P/E
- –
- EPS, last 4 quarters
- $-1.00
- Dividend yield
- –
- Day range
- –
- 52-week range
- $12.04 to $31.44
- Average volume
- –
- Previous close
- $18.49
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $50.33, +172.2% from here
$42.00now $18.49$65.00
Earnings
next estimate $-0.2700Next report Nov 19, 2026
Sep 2025
0.0%
Dec 2025
+20.7%
Mar 2026
-14.8%
Jun 2026
+25.8%
estimate reported, and the surprise
Financials
No quarterly figures from the source.
News
8 latest- Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know.The Motley Fool · Jul 23, 2026
- Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026?Zacks · Jul 2, 2026
- AtaiBeckley Reflects a New Push for Rapid-Acting Mental Health DrugsZacks · Jul 2, 2026
- AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026Zacks · Jul 2, 2026
- GH Reports Primary Endpoint Met In Phase 2a For GH001 In Treating Post-Partum Depression RTTNews · Jun 5, 2026
- GH Research Welcomes White House Order On Mental Health Treatments; Stock Up RTTNews · Apr 20, 2026
- GH Research (GHRS) Price Target Increased by 18.94% to 40.04Fintel · Mar 27, 2026
- Stocks Finish Higher on Strength in Chip Makers and Energy ProducersBarchart · Jan 6, 2026
The company
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- Europe
- Website
- ghres.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.